Given that PARP1 has an important role in DDR, a novel therapeutic targeting PARP1 has been developed to treat cancers through increasing tumor sensitivity to chemotherapeutic agents and also through inducing “synthetic lethality” in cells [78]. This evidence concerns the gene PARP1 and neoplasm.